vs
INTERNATIONAL BANCSHARES CORP（IBOC）与Orthofix Medical Inc.（OFIX）财务数据对比。点击上方公司名可切换其他公司
Orthofix Medical Inc.的季度营收约是INTERNATIONAL BANCSHARES CORP的1.0倍（$219.9M vs $217.7M），INTERNATIONAL BANCSHARES CORP净利率更高（62.3% vs -1.0%，领先63.3%），INTERNATIONAL BANCSHARES CORP同比增速更快（4.5% vs 2.0%），INTERNATIONAL BANCSHARES CORP自由现金流更多（$472.9M vs $16.8M），过去两年Orthofix Medical Inc.的营收复合增速更高（8.0% vs 2.8%）
国际银行股份公司（International Bancshares Corporation）是总部位于美国得克萨斯州拉雷多的银行控股公司，核心子公司为国际商业银行。目前集团通过旗下银行子公司运营217个营业网点、315台自动柜员机，服务覆盖得克萨斯州、俄克拉荷马州的88个城镇社区。
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
IBOC vs OFIX — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $217.7M | $219.9M |
| 净利润 | $106.9M | $-2.2M |
| 毛利率 | — | 71.1% |
| 营业利润率 | 62.8% | 0.2% |
| 净利率 | 62.3% | -1.0% |
| 营收同比 | 4.5% | 2.0% |
| 净利润同比 | -7.1% | 92.4% |
| 每股收益（稀释后） | $1.71 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $217.7M | $219.9M | ||
| Q3 25 | $218.1M | $205.6M | ||
| Q2 25 | $208.2M | $203.1M | ||
| Q1 25 | $198.2M | $193.6M | ||
| Q4 24 | $208.3M | $215.7M | ||
| Q3 24 | $211.8M | $196.6M | ||
| Q2 24 | $207.8M | $198.6M | ||
| Q1 24 | $205.8M | $188.6M |
| Q4 25 | $106.9M | $-2.2M | ||
| Q3 25 | $108.4M | $-22.8M | ||
| Q2 25 | $100.1M | $-14.1M | ||
| Q1 25 | $96.9M | $-53.1M | ||
| Q4 24 | $115.1M | $-29.1M | ||
| Q3 24 | $99.8M | $-27.4M | ||
| Q2 24 | $97.0M | $-33.4M | ||
| Q1 24 | $97.3M | $-36.0M |
| Q4 25 | — | 71.1% | ||
| Q3 25 | — | 72.2% | ||
| Q2 25 | — | 68.7% | ||
| Q1 25 | — | 62.8% | ||
| Q4 24 | — | 69.0% | ||
| Q3 24 | — | 68.7% | ||
| Q2 24 | — | 67.8% | ||
| Q1 24 | — | 67.5% |
| Q4 25 | 62.8% | 0.2% | ||
| Q3 25 | 62.6% | -8.3% | ||
| Q2 25 | 60.5% | -7.9% | ||
| Q1 25 | 61.1% | -25.2% | ||
| Q4 24 | 64.2% | -5.3% | ||
| Q3 24 | 60.0% | -9.6% | ||
| Q2 24 | 60.1% | -12.5% | ||
| Q1 24 | 59.9% | -15.6% |
| Q4 25 | 62.3% | -1.0% | ||
| Q3 25 | 49.7% | -11.1% | ||
| Q2 25 | 48.1% | -6.9% | ||
| Q1 25 | 48.9% | -27.4% | ||
| Q4 24 | 71.5% | -13.5% | ||
| Q3 24 | 47.1% | -13.9% | ||
| Q2 24 | 46.7% | -16.8% | ||
| Q1 24 | 47.3% | -19.1% |
| Q4 25 | $1.71 | $-0.05 | ||
| Q3 25 | $1.74 | $-0.57 | ||
| Q2 25 | $1.61 | $-0.36 | ||
| Q1 25 | $1.56 | $-1.35 | ||
| Q4 24 | $1.85 | $-0.76 | ||
| Q3 24 | $1.60 | $-0.71 | ||
| Q2 24 | $1.56 | $-0.88 | ||
| Q1 24 | $1.56 | $-0.95 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $5.5B | $82.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $3.3B | $450.0M |
| 总资产 | $16.6B | $850.6M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $5.5B | $82.0M | ||
| Q3 25 | $5.6B | $62.9M | ||
| Q2 25 | $5.8B | $65.6M | ||
| Q1 25 | $5.6B | $58.0M | ||
| Q4 24 | $5.4B | $83.2M | ||
| Q3 24 | $5.8B | $30.1M | ||
| Q2 24 | $5.7B | $26.4M | ||
| Q1 24 | $5.7B | $27.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | $157.2M | ||
| Q2 25 | — | $157.0M | ||
| Q1 25 | — | $156.9M | ||
| Q4 24 | — | $157.0M | ||
| Q3 24 | — | $118.5M | ||
| Q2 24 | — | $118.0M | ||
| Q1 24 | — | $118.2M |
| Q4 25 | $3.3B | $450.0M | ||
| Q3 25 | $3.1B | $442.5M | ||
| Q2 25 | $3.0B | $458.3M | ||
| Q1 25 | $2.9B | $458.3M | ||
| Q4 24 | $2.8B | $503.1M | ||
| Q3 24 | $2.7B | $525.9M | ||
| Q2 24 | $2.6B | $546.0M | ||
| Q1 24 | $2.5B | $570.3M |
| Q4 25 | $16.6B | $850.6M | ||
| Q3 25 | $16.6B | $832.6M | ||
| Q2 25 | $16.5B | $837.2M | ||
| Q1 25 | $16.3B | $823.1M | ||
| Q4 24 | $15.7B | $893.3M | ||
| Q3 24 | $15.9B | $867.9M | ||
| Q2 24 | $15.5B | $882.0M | ||
| Q1 24 | $15.4B | $906.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | 0.36× | ||
| Q2 25 | — | 0.34× | ||
| Q1 25 | — | 0.34× | ||
| Q4 24 | — | 0.31× | ||
| Q3 24 | — | 0.23× | ||
| Q2 24 | — | 0.22× | ||
| Q1 24 | — | 0.21× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $491.1M | $27.7M |
| 自由现金流经营现金流 - 资本支出 | $472.9M | $16.8M |
| 自由现金流率自由现金流/营收 | 217.2% | 7.6% |
| 资本支出强度资本支出/营收 | 8.3% | 4.9% |
| 现金转化率经营现金流/净利润 | 4.59× | — |
| 过去12个月自由现金流最近4个季度 | $809.9M | $-1.3M |
8季度趋势，按日历期对齐
| Q4 25 | $491.1M | $27.7M | ||
| Q3 25 | $115.2M | $12.4M | ||
| Q2 25 | $95.5M | $11.6M | ||
| Q1 25 | $140.5M | $-18.4M | ||
| Q4 24 | $473.9M | $23.7M | ||
| Q3 24 | $116.5M | $11.7M | ||
| Q2 24 | $107.2M | $9.0M | ||
| Q1 24 | $135.4M | $-18.6M |
| Q4 25 | $472.9M | $16.8M | ||
| Q3 25 | $112.2M | $2.5M | ||
| Q2 25 | $91.6M | $4.5M | ||
| Q1 25 | $133.1M | $-25.1M | ||
| Q4 24 | $459.8M | $15.2M | ||
| Q3 24 | $109.6M | $6.3M | ||
| Q2 24 | $104.9M | $-360.0K | ||
| Q1 24 | $128.9M | $-29.1M |
| Q4 25 | 217.2% | 7.6% | ||
| Q3 25 | 51.5% | 1.2% | ||
| Q2 25 | 44.0% | 2.2% | ||
| Q1 25 | 67.1% | -13.0% | ||
| Q4 24 | 220.8% | 7.0% | ||
| Q3 24 | 51.7% | 3.2% | ||
| Q2 24 | 50.5% | -0.2% | ||
| Q1 24 | 62.6% | -15.4% |
| Q4 25 | 8.3% | 4.9% | ||
| Q3 25 | 1.3% | 4.8% | ||
| Q2 25 | 1.9% | 3.5% | ||
| Q1 25 | 3.7% | 3.5% | ||
| Q4 24 | 6.8% | 4.0% | ||
| Q3 24 | 3.3% | 2.7% | ||
| Q2 24 | 1.1% | 4.7% | ||
| Q1 24 | 3.2% | 5.6% |
| Q4 25 | 4.59× | — | ||
| Q3 25 | 1.06× | — | ||
| Q2 25 | 0.95× | — | ||
| Q1 25 | 1.45× | — | ||
| Q4 24 | 4.12× | — | ||
| Q3 24 | 1.17× | — | ||
| Q2 24 | 1.11× | — | ||
| Q1 24 | 1.39× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
IBOC
暂无分部数据
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
